Core Viewpoint - Hanwei Technology (300007) expects a net profit attributable to shareholders of the listed company for the year 2025 to be between 125 million and 175 million yuan, representing a growth of 63.01% to 128.22% compared to the same period last year [1] Financial Performance - The projected net profit range for 2025 is 125 million to 175 million yuan [1] - This represents a significant increase of 63.01% to 128.22% year-on-year [1]

智通财经APP讯，汉威科技(300007.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润 1.25亿元至1.75亿元，同比增长63.01%至128.22%;扣除非经常性损益后的净利润4000万元至6000万元。 ...

Core Viewpoint - The article highlights the investment strategy of Hu Zhongyuan, focusing on AI applications and robotics, while maintaining a cautious approach with a reduced equity position in his funds [1][4]. Fund Performance - Hu Zhongyuan manages a total of 33.2 billion yuan across five funds, achieving an annualized return of 26% over 6.8 years [6]. - The flagship fund, Huashang Runfeng Flexible Allocation Mixed A, has shown a remarkable return of 85.02% in 2025, significantly outperforming its benchmark and the CSI 300 index [11][12]. - The fund's net value has consistently increased, with a 4.28% growth in the current year [11]. Investment Strategy - The fund maintained an equity position below 45% during market downturns in 2022 and 2023, effectively controlling drawdowns [13]. - Starting in Q1 2024, Hu Zhongyuan increased the equity position to over 90%, but has since reduced it to around 50% in Q3 2025, indicating a strategic shift in response to market conditions [15]. - The top ten holdings have become more diversified, with the concentration of the top ten stocks decreasing from 45% to 23% [15]. Sector Focus - The fund is now focusing on AI application hardware and robotics, with investments spread across sectors such as electronics, communications, media, machinery, home appliances, automotive, electric power equipment, and medical devices [17]. - Recent adjustments include new positions in key consumer electronics companies, indicating a shift from upstream technology to downstream applications [17]. Key Holdings - The top ten holdings in Q4 2025 include new entries like Crystal Optoelectronics, GoerTek, and Luxshare Precision, reflecting a strategic pivot towards consumer electronics [17][19]. - The fund has also increased its stakes in companies involved in the robotics sector, such as Sanhua Intelligent Control and Top Group, while introducing new positions in Jiangsu Leili [19].

证券代码：300007 证券简称：汉威科技 公告编号：2026-010 汉威科技集团股份有限公司 2025 年度，公司业绩变动主要原因如下： 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为正值且属于同向上升 50%以上情形 单位：万元 | 项 目 | | 本报告期 | | | 上年同期 | | --- | --- | --- | --- | --- | --- | | 归属于上市公司 | | 12,500 | ～ | 17,500 | 7,668.03 | | 股东的净利润 | 比上年同期增长 | 63.01% | ～ | 128.22% | | | 扣除非经常性损 | | 4,000 | ～ | 6,000 | 563.33 | | 益后的净利润 | 比上年同期增长 | 610.06% | ～ | 965.10% | | 二、与会计师事务所沟通情况 本次业绩预告未经会计师事务所审计。公司已就本次业 ...

证券代码：300007 证券简称：汉威科技 公告编号：2026-009 董 事 会 2026 年 1 月 28 日 汉威科技集团股份有限公司（以下简称"公司"）于 2026 年 1 月 16 日召开 了第六届董事会第二十八次会议，审议通过了《关于公司董事会换届选举暨提名 第七届董事会独立董事候选人的议案》，提名刘之斐先生为第七届董事会独立董 事候选人，任期自 2026 年第一次临时股东会审议通过之日起三年。 截至公司 2026 年第一次临时股东会通知发出之日，刘之斐先生尚未取得独 立董事资格证书，根据深圳证券交易所的有关规定，刘之斐先生已书面承诺参加 最近一期独立董事资格培训并取得深圳证券交易所认可的独立董事资格证书。 近日，公司董事会收到独立董事候选人刘之斐先生的通知，其已按照相关规 定参加了深圳证券交易所举办的上市公司独立董事任前培训(线上)，并取得了由 深圳证券交易所创业企业培训中心颁发的《上市公司独立董事培训证明》。 特此公告。 汉威科技集团股份有限公司 汉威科技集团股份有限公司 关于独立董事候选人取得独立董事资格证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误 ...

Group 1 - Tianqi Co., Ltd. has entered the brain-computer interface (BCI) sector by investing in Suzhou Huahui Chip, focusing on high-density flexible neural electrode technology, achieving animal testing stages, and becoming a key player in domestic BCI hardware localization. The developed flexible neural electrode has 1024 channels, with signal acquisition precision and anti-interference capabilities at an internationally advanced level. The company has also completed biocompatibility surface modification technology to reduce inflammation after electrode implantation, with core patents authorized by the National Intellectual Property Administration [1][2][3] - Innovation Medical, through its subsidiary Boling Brain Machine, is one of the first companies in China to commercialize BCI rehabilitation products. The core product, Cyberlink AC5, was officially launched in October 2025, generating sales revenue of 114,000 yuan in 2025. Another product, Cyberlink AM5, has completed multi-center clinical trials and is progressing through the approval process. The company plans to establish five additional clinical cooperation centers to accelerate the application of BCI technology in treating neurological diseases [4][5][6] - iFlytek is a leading company in the non-invasive BCI field, leveraging its artificial intelligence technology to develop BCI collaborative technology. The company has established long-term partnerships with universities for research and development. Its non-invasive BCI system has been piloted in 120 schools nationwide, improving student attention by 30%. In the medical field, a collaboration with Beijing Tiantan Hospital has achieved a 92% accuracy rate in identifying abnormal brain signals for epilepsy [7][8][9] Group 2 - Jiahe Intelligent focuses on the research and mass production of BCI hardware, particularly EEG acquisition devices and core components, serving both consumer and medical-grade markets. The company has achieved large-scale production of EEG acquisition headphones with a signal recognition accuracy of 92%, primarily used in sleep monitoring and attention training. It plans to expand into overseas BCI hardware markets by 2026 [10][11][12] - Tom Cat is the first company in China to apply BCI technology in consumer scenarios, focusing on interactive games and rehabilitation training products. The company launched a mind-controlled game product in 2025, which quickly gained over 500,000 users. It also collaborates with rehabilitation institutions to develop BCI rehabilitation training systems, showing a 35% average improvement in patient motor function scores [13][14][15] - Hanwei Technology, through its subsidiary Weisheng Technology, is a leading company in the EEG sensor field, with an annual shipment of over 2 million units. The company has developed an epilepsy early warning system with an 88% accuracy rate in clinical tests. It also focuses on flexible pressure sensors for invasive BCI electrodes, addressing industry pain points [16][17][18] Group 3 - StarNet Ruijie leverages its network communication technology to develop low-power, high-stability EEG signal transmission systems and data encryption modules, becoming a core supplier for BCI data links. The developed transmission system supports real-time transmission of 1024-channel EEG signals with a latency of less than 10ms and a stability of 99.9% [19][20][21] - Yijiahe focuses on the integration of BCI and embodied intelligent robots, exploring applications in smart healthcare. The company has signed a strategic cooperation agreement to develop real-time emotional companionship and brain-controlled robots, enhancing the emotional care capabilities of robots [22][23][24] - Lihua Technology is focused on incubating and investing in the BCI sector, successfully incubating three high-tech companies in the field. The company collaborates with the Shenzhen Institute of Advanced Technology to provide comprehensive services for incubated companies, addressing development pain points [25][26][27] Group 4 - Sanbo Neurosurgery is a leading private hospital in the neurosurgery field, focusing on the clinical application and research of BCI. The company has successfully conducted an interventional BCI surgery, accumulating valuable experience for clinical applications. It is also recruiting participants for ongoing clinical trials [28][29][30] - Shiyun Circuit is a core enterprise in the PCB field, providing customized PCB products for BCI devices. The company focuses on high-density, flexible PCB designs, achieving low signal loss rates below 2% [31][32][33] - Meihua Medical is a leading supplier of core components for BCI, having entered the core supply chain for invasive BCI products. The company has developed components that have passed biocompatibility tests, ensuring long-term stability and safety for implanted devices [34][35][36]

Group 1 - The humanoid robot concept has shown initial strength in the market, with companies like Baida Precision and Tianqi Co., Ltd. both hitting the daily limit up [1] - Zhongkong Technology has increased by over 10%, indicating strong investor interest in the sector [1] - Other companies such as Zhaofeng Co., Lushan New Materials, Hanwei Technology, Green Harmonics, and Fuda Co., Ltd. have also seen significant gains, contributing to the overall positive trend in the humanoid robot industry [1]

Core Insights - A breakthrough in Alzheimer's treatment was observed when a focused ultrasound surgery unexpectedly improved the cognitive function of a patient suffering from both Alzheimer's and muscle tension disorder, challenging the traditional belief that Alzheimer's is irreversible [1] - The global prevalence of Alzheimer's is high, with nearly 17 million patients in China alone, leading to significant caregiving pressures on families [1] Group 1: Innovative Approaches - The research team led by Professor Sun Bomin is exploring a new pathway for Alzheimer's treatment by using high-energy ultrasound to directly stimulate brain neural circuits, moving away from conventional low-energy ultrasound-assisted drug therapies [2] - After a year of preparation, clinical trials were initiated, showing an average cognitive improvement rate of approximately 50% among the first seven moderate to severe patients treated, with some patients regaining household skills and emotional connections [2] Group 2: Market Potential - The global brain-computer interface (BCI) market is projected to grow from approximately $2.62 billion in 2024 to $2.94 billion in 2025, and is expected to reach $12.4 billion by 2034, with a compound annual growth rate of 17.35% over the next decade [2] - In China, the BCI market is anticipated to grow from 3.2 billion yuan in 2024 to 6.14 billion yuan by 2028, supported by national strategies aimed at fostering high-tech industries [2] Group 3: Companies to Watch - Companies such as Rock Mountain Technology, Hanwei Technology, Sanbo Brain Science, Innovation Medical, Dongfang Zhongke, Xiangyu Medical, Entropy Technology, Chengyitong, Weisi Medical, Microland, Aipeng Medical, and Beiyikang are suggested for attention in this emerging field [3]

行 华福证券 机械设备 2026 年 01 月 25 日 业 研 究 机械设备 马斯克力推 Optimus，2027 年底拟向公众开售 行 业 定 特斯拉 CEO 马斯克将发展重心投向 Optimus 人形机器人，旨在推 动公司转型为估值 25 万亿美元的机器人企业，该业务价值预计将远超 现有汽车业务。这一战略布局也是其千亿薪资方案的核心，彰显了对 机器人赛道未来潜力的坚定信心。 定下宏大愿景，人形机器人发展蓝图清晰 期 报 告 马斯克公开表示，2027 年底将开始向公众销售 Optimus 人形机器 人，同时大胆预言 2026 年将实现通用人工智能，未来三年内该类 AI 机器人可能在外科手术等领域超越人类专家，2040 年全球机器人数量 或将达到 100 亿台甚至更多。特斯拉已筹备扩建得克萨斯超级工厂， 规划建设人形机器人专用量产设施，目标实现年产能 1000 万台，且已 在机器人动态平衡、灵巧手升级等技术方面取得突破。 人形机器人造福全人类，未来有望像汽车般普及 中国机器人网表示，目前来看，发展足够智能的人形机器人把人 类社会的重复性体力劳动接管过去将会是一个造福全人类的科技大方 向。据高工移动机器人，英 ...

Investment Rating - The industry rating is "Outperform the Market," indicating that the overall return of the industry is expected to exceed the market benchmark index by more than 5% over the next 6 months [14]. Core Insights - A breakthrough in Alzheimer's treatment was observed when a focused ultrasound surgery unexpectedly improved the cognitive function of a patient, challenging the traditional belief that Alzheimer's is irreversible. This condition affects nearly 17 million patients in China, leading to significant caregiving burdens [4][5]. - The research team led by Professor Sun Bomin is exploring a new approach using high-energy ultrasound to directly stimulate brain neural circuits, with initial clinical trials showing an average improvement rate of about 50% among seven moderate to severe patients [5]. - The global brain-computer interface (BCI) market is projected to grow rapidly, with an estimated size of approximately $2.62 billion in 2024, reaching $2.94 billion in 2025, and potentially growing to $12.4 billion by 2034, reflecting a compound annual growth rate of 17.35% over the next decade [6]. Summary by Sections Industry Overview - The report highlights the significant unmet medical need in Alzheimer's treatment and the potential for innovative therapies to emerge from recent clinical findings [4][5]. Market Potential - The brain-computer interface market is expected to see substantial growth, with specific projections for both global and Chinese markets, indicating a strategic focus on high-tech industries as outlined in national economic plans [6]. Investment Recommendations - The report suggests monitoring companies such as Yanshan Technology, Hanwei Technology, Sanbo Brain Science, and others, which are positioned to benefit from advancements in the BCI and related technologies [6].